The round was also supported by Partners Innovation Fund, the company said in a statement.
Editas is focused on using genome editing technology into a new class of human therapeutics that enables molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Polaris Partners principal and interim president of Editas Kevin Bitterman said, “Editas is exclusively positioned to leverage the very latest in genome editing to develop life-changing medicines for patients.
“Our suite of foundational intellectual property, combined with the proprietary know-how of our founding team and our financial resources, will enable us to rapidly translate these groundbreaking discoveries into important medicines.”
Earlier this year Third Rock and Flagship floated their portfolio company Agios Pharmaceuticals on the Nasdaq exchange.
Copyright © 2013 AltAssets